The KRAS CARD is designed to detect seven known somatic mutations of KRAS oncogene from either fresh or formaldehyde fixed-paraffin embedded tissue samples automatically on the EncompassMDx system.

The company said the KRAS CARD assay is not cleared for diagnostic use by the US Food and Drug Administration.

Rheonix president Tony Eisenhut said until now, there has not been a fully automated system that could process the raw sample types required of molecular oncology assays.

"Our Encompass platform not only reduces the amount of time necessary to perform a KRAS assay, but it also has the potential to reduce the cost of these assays and enable a broader use in the clinic," Eisenhut added.

"Our novel assay for the detection of KRAS mutations has shown to achieve analytical sensitivity down to 0.1% as compared to current benchtop molecular assays which are capable of detecting 1% mutation."